Ningbo launches first China-CEE pharmaceutical trading platform, trial orders exceed 200 million yuan
On September 22, the Ningbo China-Central and Eastern Europe (CEE) Pharmaceutical Trading Platform officially launched in Ningbo, China. Guided by the National Healthcare Security Administration, it is the first specialized cross-border platform targeting CEE countries. During a trial run since March, it attracted nearly 500 suppliers and over 20 overseas buyers, listing more than 4,000 products. Transaction volume exceeded 200 million yuan. The platform provides product display, supply-demand matching, logistics, and settlement services to help Chinese pharmaceutical firms export.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Ningbo launches first China-Central and Eastern Europe pharmaceutical trading platform to aid drug exports
On September 22, the Ningbo China-Central and Eastern Europe (CEE) Pharmaceutical Trading (Centralized Procurement) Platform was officially launched in Ningbo, China. According to Tu Zhijun, an official from the Ningbo Municipal Healthcare Security Bureau, the platform aims to solve two core problems for pharmaceutical companies seeking to export: finding overseas buyers and managing cross-border logistics. The platform began trial operations in March 2024, and by mid-September had attracted nearly 500 suppliers, over 20 overseas buyers, and listed more than 4,000 products including active pharmaceutical ingredients (APIs) and medical equipment. Ningbo Pharma, a beneficiary, reported nearly $10 million in API and prescription drug transactions through the platform, covering most CEE markets. Smaller firms like Ningbo Cibei Medical Devices aim to increase their platform export share to 50%. The platform is the fourth international medical device trading platform guided by China's National Healthcare Security Administration, and the first specifically targeting CEE countries. It leverages Ningbo's existing trade ties with the region. The platform's operators plan to expand its reach through domestic and overseas promotional events, including in Slovenia and Slovakia, and by partnering with industry associations and foreign chambers of commerce in China.
Read sourceNingbo launches cross-border pharmaceutical trading platform with 500 suppliers and 200 million yuan in transactions
On September 22, the Ningbo Central and Eastern Europe Pharmaceutical Trading (Centralized Procurement) Platform was officially launched in Zhejiang Province, China. It is the first specialized pharmaceutical trading platform targeting Central and Eastern European countries and the fourth cross-border platform coordinated by China's National Healthcare Security Administration, following similar platforms in Guangxi, Tianjin, and Xinjiang. The platform currently hosts nearly 500 supplier enterprises and 20 overseas buyers, displaying over 4,000 pharmaceutical and medical device products across six categories. During its trial run, the platform facilitated pharmaceutical export transactions exceeding 200 million yuan (approximately $28 million). The platform aims to address challenges Chinese pharmaceutical companies face in overseas markets, including information asymmetry and complex cross-border procedures. It provides B2B services including online storefronts, real-time communication, logistics, and cross-border settlement. Officials and company representatives quoted in the article highlight the platform's role in expanding overseas market access and enhancing the international influence of Chinese pharmaceutical products, while noting that overseas pricing is determined by target market standards rather than domestic centralized procurement prices.
Ningbo China-CEE Pharmaceutical Trading Platform Launches, Exceeds 2 Billion Yuan in Trial
On September 22, the Ningbo China-CEE Pharmaceutical Trading (Centralized Procurement) Platform was officially launched in Ningbo, China. Guided by the National Healthcare Security Administration, it is the first specialized cross-border pharmaceutical trading platform targeting Central and Eastern European (CEE) countries. The platform focuses on four core functions: product showcase, supply-demand matching, comprehensive foreign trade services, and data dashboards, aiming to reduce export costs for Chinese pharmaceutical firms and expand overseas markets. During a six-month trial operation, the platform attracted nearly 500 supplier enterprises, over 20 overseas buyers, and listed more than 4,000 products across six categories including APIs, preparations, traditional Chinese medicine, medical consumables, diagnostic reagents, and medical equipment. Transaction volume exceeded 2 billion yuan. One early participant, Ningbo Menovo Pharmaceutical, reported nearly $10 million in API and finished preparation transactions, covering most CEE markets. A Ningbo Medical Insurance Bureau official stated the platform integrates online and offline functions, segmented management, and unified settlement, with plans to gradually expand and upgrade to bring more high-quality medical products to CEE markets.
Read sourceShow 2 older updatesHide older updates
Fourth International Drug and Device Trading Platform Launches, Orders Exceed 200 Million Yuan
The Ningbo China-Central and Eastern Europe Pharmaceutical Trading (Centralized Procurement) Platform officially launched on September 22, becoming the fourth international drug and device trading platform guided by China's National Healthcare Security Administration. During its trial run since March, the platform attracted nearly 500 suppliers and 20 overseas buyers, listing over 4,000 products including APIs, formulations, medical devices, and diagnostic reagents. Transaction orders have exceeded 200 million yuan, primarily for APIs. Ningbo Municipal Healthcare Security Bureau official Tu Zhijun stated the platform aims to reduce the high costs of traditional overseas market entry, such as trade fairs, and provides a channel for companies with no prior export experience. The platform covers markets beyond Central and Eastern Europe, including Europe, the Americas, and Southeast Asia. Companies like Ningbo Menovo and Guangsheng Meiyu reported gaining new customers and expanding market reach. Officials noted that international pricing is not linked to China's domestic centralized procurement prices, but Chinese regulatory standards boost product credibility. The platform is one of four such initiatives, alongside platforms led by Guangxi, Xinjiang, and Tianjin.
Read sourceNingbo China-CEE Pharmaceutical Trading Platform Launches, Aiding Drug and Device Exports
The Ningbo China-Central and Eastern Europe (CEE) Pharmaceutical Trading (Procurement) Platform officially launched on September 22, 2025, as reported by East Money. Guided by China's National Healthcare Security Administration (NHSA), the platform aims to streamline pharmaceutical and medical device exports by connecting domestic suppliers with overseas buyers. It offers product display, supply-demand matching, cross-border transactions, and comprehensive foreign trade services including logistics, customs clearance, and currency settlement. As of mid-September, nearly 500 suppliers and over 20 overseas buyers had joined, with more than 4,000 products listed and trial transaction volume exceeding 200 million yuan. Company executives, including Yao Chengzhi of Menovo and Shen Guocheng of Cixi Medical Devices, reported that the platform has helped them expand market coverage and reduce costs. Menovo stated it has achieved near-full coverage of CEE markets via the platform. The platform is part of a broader NHSA initiative to build international trading infrastructure, including similar platforms for ASEAN, Central Asia, and global medical devices. Officials and executives noted that while the platform provides a low-cost channel for new customer acquisition, its overseas visibility is still in early stages and requires further promotion.
Read source